时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
Dihydroartemisinin (DHA), an active derivative of artemisinin, exhibits broad anti-inflammatory and immunomodulatory properties; however, its mechanistic role in allergic asthma remains incompletely defined.；Moreover, corticosteroid resistance and heterogeneous therapeutic responses remain major clinical challenges, underscoring the need for novel therapeutic strategies that target upstream molecular mechanisms driving airway inflammation and remodeling [6, 10].；However, whether DHA exerts protective effects against allergic airway inflammation through modulation of PI3K-AKT centered signaling networks remains largely unclear.
方法
These predictions were validated in a house dust mite (HDM) induced murine asthma model and HDM stimulated human bronchial epithelial (HBE) cells using histopathology, flow cytometry, RT-qPCR, Western blotting, ELISA, and molecular docking.；Gene Ontology (GO) enrichment (biological processes, cellular components, molecular functions) and Kyoto Encyclopedia of Genes and Page 5/27 Genomes (KEGG) pathway analyses were conducted via the Weishengxin platform (http://www.bioinformatics.com.cn/), with statistical significance set at adjusted p < 0.05.；Animals and housing Twenty male SPF C57BL/6 mice (8 weeks old, 20 ± 2 g) were purchased from the Guangdong Experimental Animal Center (Guangzhou, China).；All procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Guangdong Medical University and complied with the NIH Guide for the Care and Use of Laboratory Animals
核心结论
In vivo, DHA markedly attenuated airway inflammation, reduced eosinophil and neutrophil infiltration, and decreased Th2 cytokine production.；Conclusions DHA alleviates allergic airway inflammation predominantly through suppression of the PI3K-AKT signaling axis, thereby modulating epithelial inflammatory responses and type 2 immunity.；These findings provide mechanistic insight into DHA-mediated immunoregulation and support its potential repositioning as a therapeutic candidate for allergic asthma. ‖ 结论：Together, our results provide a mechanistic basis for further exploration of DHA as a network-oriented immunomodulatory agent and support the rationale for targeting PI3K-AKT centered signaling networks in the treatment of allergic airway diseases.
局限
Introduction Allergic asthma is a chronic and heterogeneous inflammatory airway disease characterized by persistent airway inflammation, reversible airflow limitation, mucus hypersecretion, and progressive airway remodeling.；Despite these advances, several limitations warrant further investigation.；Second, asthma exhibits marked clinical heterogeneity, including eosinophilic, neutrophilic, mixed granulocytic, and paucigranulocytic phenotypes.
对本项目的价值
★☆☆☆☆ 炎症衰老是几乎所有慢性老年病的公共通路，也是最有希望做「抗炎但保留免疫」解耦的靶点。
全文来源
出版商 OA PDF（正文 52,098 字符，已过 DOI 逐字 / 标题指纹归属校验）
原文题录
- 英文标题：Dihydroartemisinin alleviates allergic airway inflammation by suppressing the PI3K-AKT signaling axis: integrated network pharmacology and experimental validation.
- 期刊与标识：Respir Res · PMID 42963570 · DOI 10.1186/s12931-026-03956-0
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。